# DESCRIPTION

## STATEMENT AS TO FEDERALLY SPONSORED RESEARCH

- disclose government funding

## FIELD OF THE INVENTION

- define field of invention

## BACKGROUND OF THE INVENTION

- introduce ventricular enlargement
- describe schizophrenia and 22q11DS
- discuss Dgcr8 and miRNA depletion
- motivate invention

## SUMMARY OF THE INVENTION

- introduce treatment for ventricular enlargement
- describe Drd1 inhibitor method
- describe miR-382-3p and miR-674-3p method
- specify diseases associated with ventricular enlargement
- describe administration methods
- describe effects on ventricular enlargement
- describe effects on ciliary beating
- describe effects on dopamine receptor expression
- describe effects on miR-382-3p and miR-674-3p levels
- specify subject conditions
- describe additional treatment agents
- describe vector selection
- describe determining efficacy of treatment
- describe determining likelihood of disease
- describe kit for determining efficacy
- describe pharmaceutical composition and dosage form

## DETAILED DESCRIPTION OF THE INVENTION

- describe discovery of miR-382-3p and/or miR-674-3p depletion in 22q11 deletion syndrome and its effects

### Definitions

- define schizophrenia
- define microRNA (miRNA)
- describe miRNA processing
- define functional derivative of a miRNA
- define miRNA mimic
- describe miRNA mimic design and function
- define vector, expression vector, and expression construct
- describe promoter and enhancer elements
- describe transcription terminator/polyadenylation signals
- describe 5'-UTR sequences
- define marker in expression vector
- describe selectable markers
- define treat, treatment, and therapeutically effective
- define pharmaceutically acceptable
- define combination of a composition and at least a second pharmaceutically active ingredient
- define carrier
- define individual, subject, or animal
- define associated with
- define about

### Therapeutic Methods

- provide therapeutic method for treating disease associated with ventricular enlargement
- specify inhibitor of Drd1 for treatment
- describe gene editing of Drd1 gene in ependymal cells
- provide alternative therapeutic method using miR-382-3p and/or miR-674-3p
- specify diseases associated with ventricular enlargement
- describe sequences of miR-382-3p and/or miR-674-3p
- outline expression of miR-382-3p and/or miR-674-3p from viral vectors
- describe use of promoters for expressing miR-382-3p and/or miR-674-3p
- provide alternative expression of miR-382-3p and/or miR-674-3p from plasmids
- define therapeutic methods
- describe plasmid expression
- outline miRNA synthesis
- discuss design elements of synthetic miRNA
- describe delivery enhancement methods
- detail liposome preparation
- explain opsonization-inhibiting moieties
- describe stealth liposomes
- outline alternative delivery methods
- discuss combination therapy
- describe increasing Dgcr8 expression
- outline genetic correction methods

### Compositions and Methods of Administration

- introduce Drd1 inhibitor administration
- describe pharmaceutical compositions
- outline combination therapies
- introduce miR-382-3p and/or miR-674-3p administration
- describe pharmaceutical compositions
- outline combination therapies
- list diseases associated with ventricular enlargement
- describe antipsychotics
- outline miRNA molecule modifications
- describe miRNA synthesis and purification
- formulate pharmaceutical preparation
- mix with pharmaceutical carrier
- describe pharmaceutically acceptable derivatives
- administer inside ventricles
- administer intranasally
- describe nasal delivery-enhancing agents
- administer through various methods
- describe additional ingredients for enhancing nasal delivery
- enhance activity or physical stability
- describe membrane penetration-enhancing agents
- list examples of membrane penetration-enhancing agents
- provide references for membrane penetration-enhancing agents
- list absorption enhancers
- describe nasal delivery-enhancing agents
- outline formulation preparation
- specify delivery volume
- describe liquid composition preparation
- describe solid composition preparation
- outline lyophilization process
- describe delivery devices
- outline nasal spray administration
- describe powder dispersion
- outline blood-brain barrier crossing agents
- specify administration regimen
- introduce compositions and methods of administration
- describe administration routes
- list suitable enteral administration routes
- list suitable parenteral administration routes
- describe formulation of compositions
- list components of solutions or suspensions
- describe antimicrobial agents
- describe antioxidants
- describe chelating agents
- describe buffers
- describe tonicity adjusters
- describe solubilizing methods
- describe pharmaceutically acceptable derivatives
- describe solid dosage forms
- list binders
- list lubricants
- list diluents
- list disintegrating agents
- list coloring agents
- list flavoring agents
- list wetting agents
- describe liquid oral dosage forms
- describe parenteral administration
- describe packaging and labeling

### Diagnostic Methods

- introduce diagnostic methods for ventricular enlargement diseases
- describe method for determining efficacy of treatment
- outline steps for determining miR-382-3p and/or miR-674-3p levels
- compare levels to determine treatment efficacy
- describe method for determining likelihood of developing disease
- outline steps for determining miR-382-3p and/or miR-674-3p levels
- compare levels to determine likelihood of disease
- describe method for determining likelihood of developing disease using Dgcr8 gene mutations
- outline steps for determining Dgcr8 gene mutations and Drd1 levels
- compare levels to determine likelihood of disease
- describe additional diagnostic methods
- outline measurement techniques for miR-382-3p and/or miR-674-3p levels

### Kits of the Invention

- introduce kits for diagnosing ventricular enlargement diseases
- describe kit components, including primers, probes, and reagents
- outline optional kit components and features

## EXAMPLES

- provide illustrative examples

### Example 1: Materials and Methods

- describe animal models
- outline magnetic resonance imaging protocol
- detail transmission and scanning electron microscopy procedures
- describe immunogold labeling process
- outline microbeads-based ependymal flow assay
- detail software toolkit for tracing fluorescent beads
- describe ex vivo ciliary beating frequency measurements
- outline in vivo ciliary beating frequency measurements
- detail quantitative RT-qPCR protocol
- specify primers used for miRNA and mRNA analysis
- outline loading controls and normalization procedure
- generate miRNA overexpression plasmids
- generate miRNA sponge constructs
- generate Drd1Δ7bp and Drd1Δ13bp mice
- perform luciferase assay
- perform viral infections and surgery
- perform western blotting
- perform histologic analysis and immunohistochemistry
- perform super-resolution microscopy
- collect and analyze cerebrospinal fluid
- perform miRNA microarray analysis

### Example 2: Haploinsufficiency of the 22q11DS Gene Dgcr8 Causes Progressive Ventriculomegaly

- analyze MRI data in Df(16)1/+ murine models
- examine neuroanatomical features in mice
- investigate ventricular volume changes

### Example 3: Slower Ependymal Flow and Ciliary Beating in the Lateral Ventricles of Dgcr8+/− Mice

- examine ependymal flow and ciliary beating in WT and Dgcr8+/− mice
- measure ciliary beating frequency using linescan fluorescent imaging

### Example 4: Dgcr8 Haploinsufficiency does not Affect Ependymal Cell Structure or Planar Polarity

- investigate ependymal cell structure and planar polarity in Dgcr8+/− mice

### Example 5: Dysregulation of the Dopamine Receptor Drd1 in Ependymal Cells of Dgcr8+/− Mice

- examine dopamine receptor expression in ependymal cells
- investigate Drd1 regulation by Dgcr8 and its effect on ciliary beating

### Example 6: Depleting miR-382-3p or miR-674-3p or Deleting their Seed Sites on Drd1 3′UTR Decelerates Ependymal Ciliary Beating and Mediates Ventriculomegaly

- identify miRNAs involved in Dgcr8-miRNA-Drd1 mechanism
- analyze miRNA expression in Dgcr8+/− mice
- investigate miRNA-mediated regulation of Drd1
- generate mice with deletions of miRNA seed sites on Drd1 3′UTR
- examine ventricular volume changes in these mice

### Example 7: Replenishing miR-382-3p or miR-674-3p Rescues the Cilia-Beating Deficit and Ventriculomegaly in 22q11DS Mice

- overexpress miR-382-3p or miR-674-3p in ependymal cells
- examine rescue of cilia-beating deficit and ventriculomegaly
- investigate effects on Drd1 mRNA levels and ventricular volume

## CONCLUSIONS

- summarize ventricular enlargement in SCZ
- motivate 22q11DS as a model of SCZ
- describe Drd1 expression in ependymal cells
- discuss limitations of aqueduct stenosis and CSF homeostasis
- contrast ventricular enlargement in 22q11DS with hydrocephalus
- summarize evidence for ventricular enlargement in SCZ
- discuss genetic influences on ventricular enlargement
- motivate ciliogenesis and ciliary beating in ventriculomegaly
- describe functional defects of motile cilia in PCD
- summarize Dgcr8-(miR-382-3p/miR-674-3p)-Drd1 mechanism in ventricul

